Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) EPS (Weighted Average and Diluted) (2024 - 2025)

Prelude Therapeutics' EPS (Weighted Average and Diluted) history spans 2 years, with the latest figure at -$0.2 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 47.37% year-over-year to -$0.2; the TTM value through Dec 2025 reached -$1.29, up 23.67%, while the annual FY2025 figure was -$1.29, 23.21% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.2 at Prelude Therapeutics, up from -$0.26 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.2 in Q4 2025 and bottomed at -$0.46 in Q2 2024.